XNCR logo

Xencor (XNCR) Company Overview

Profile

Full Name:

Xencor, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

December 3, 2013

Indexes:

Not included

Description:

Xencor, Inc. is a biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and other protein therapeutics for the treatment of serious diseases (oncology, autoimmune). Founded in 1997. The company's main laboratory and administrative facilities are located in Monrovia, California. Xencor, Inc.'s patent portfolio includes over 1000 issued patents and pending patent applications. To carry out most of its operations and development programs, Xencor, Inc. relies on third-party contractors and service providers. Manufacturing, testing, quality assurance, clinical monitoring, data management, and regulatory expertise are outsourced to third parties.

Key Details

Price

$16.01

Annual Revenue

$168.34 M(+2.28% YoY)

Annual EPS

-$2.08(-123.66% YoY)

Annual ROE

-18.06%

Beta

1.44

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 12, 24 Wells Fargo
Overweight
Dec 2, 24 Piper Sandler
Overweight
Nov 8, 24 BMO Capital
Outperform
Nov 7, 24 JP Morgan
Overweight
Sep 26, 24 RBC Capital
Outperform
Aug 6, 24 RBC Capital
Outperform
Aug 6, 24 BMO Capital
Outperform
Jul 31, 24 JP Morgan
Overweight
Jun 14, 24 Raymond James
Strong Buy
Jun 14, 24 RBC Capital
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks
XNCR
zacks.comJanuary 15, 2025

The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
XNCR
zacks.comJanuary 14, 2025

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
XNCR
zacks.comDecember 12, 2024

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
XNCR
zacks.comDecember 4, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Xencor: Plamotamab NHL Data Leads To RA Program Advancement
Xencor: Plamotamab NHL Data Leads To RA Program Advancement
Xencor: Plamotamab NHL Data Leads To RA Program Advancement
XNCR
seekingalpha.comNovember 22, 2024

Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00. Initiation of the phase 1b/2a study, using Plamotamab for the treatment of patients with multi-drug resistant Rheumatoid Arthritis, expected 1st half of 2025. XmAb657 is a long-acting CD19 X CD3 bispecific antibody being developed to target patients with autoimmune disorders; Phase 1 trial initiation for this program expected 2nd half of 2025.

Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
XNCR
zacks.comNovember 18, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
XNCR
zacks.comNovember 14, 2024

From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know
XNCR
zacks.comOctober 16, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Xencor Announces Upcoming Change to Board of Directors
Xencor Announces Upcoming Change to Board of Directors
Xencor Announces Upcoming Change to Board of Directors
XNCR
businesswire.comOctober 4, 2024

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar Rosa-Bjorkeson has informed the Company that she will not stand for reelection to the Company's Board of Directors at the 2025 Annual Meeting of Stockholders. Ms. Rosa-Bjorkeson has served as a director since 2019 and plans to pursue another business opportunity. Xencor will.

Xencor: Vudalimab Development Along With Hidden Gem Candidate
Xencor: Vudalimab Development Along With Hidden Gem Candidate
Xencor: Vudalimab Development Along With Hidden Gem Candidate
XNCR
seekingalpha.comSeptember 12, 2024

Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Xencor?
  • Does Xencor pay dividends?
  • What sector is Xencor in?
  • What industry is Xencor in?
  • What country is Xencor based in?
  • When did Xencor go public?
  • Is Xencor in the S&P 500?
  • Is Xencor in the NASDAQ 100?
  • Is Xencor in the Dow Jones?
  • When was Xencor's last earnings report?
  • When does Xencor report earnings?
  • Should I buy Xencor stock now?

What is the ticker symbol for Xencor?

The ticker symbol for Xencor is NASDAQ:XNCR

Does Xencor pay dividends?

No, Xencor does not pay dividends

What sector is Xencor in?

Xencor is in the Healthcare sector

What industry is Xencor in?

Xencor is in the Biotechnology industry

What country is Xencor based in?

Xencor is headquartered in United States

When did Xencor go public?

Xencor's initial public offering (IPO) was on December 3, 2013

Is Xencor in the S&P 500?

No, Xencor is not included in the S&P 500 index

Is Xencor in the NASDAQ 100?

No, Xencor is not included in the NASDAQ 100 index

Is Xencor in the Dow Jones?

No, Xencor is not included in the Dow Jones index

When was Xencor's last earnings report?

Xencor's most recent earnings report was on Nov 6, 2024

When does Xencor report earnings?

The next expected earnings date for Xencor is Feb 27, 2025

Should I buy Xencor stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions